Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC

 Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC

Shots:

  • The companies plan to conduct a P-I/IIa trial assessing the safety and anti-tumor activity of SNK01 + gemcitabine/carboplatin or gemcitabine/carboplatin + Erbitux (cetuximab) in patients with LA or mNSCLC after prior TKI therapy
  • NKMax will sponsor the study while Merck KGaA will supply cetuximab (250 mg/m2, wq, IV) for P- I/IIa trial in NSCLC patients. The 1EPs of the study is to assess the safety and drug tolerance of SNK01 while 2EPs is to get efficacy assessments on the combination treatments
  • Both the companies will have access to the data of the clinical study

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Glassdoor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post